Clinical Trial

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-11-20; most recent amendment 2026-02-06.
Status change: Enrolling by Invitation → Active, Not Recruiting 2023-02-13
Trial Details
NCT Number NCT04645212
Lead Sponsor Adverum Biotechnologies, Inc.
Conditions Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Enrollment 23 participants
Start Date 2020-12-14
Primary Completion 2030-06-26 (estimated)
Study Completion 2030-06-26 (estimated)
Updated on ClinicalTrials.gov 2026-02-10